Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia.
Sun SL, Wu JZ, Wang JJ, Zhou H, Zhang CQ, Tong ZJ, Wang YB, Sha JK, Wang QX, Liu JC, Zheng XR, Li QQ, Zhang MY, Yang J, Wei TH, Wang ZX, Yu YC, Ding N, Leng XJ, Xue X, Li HM, Dai WC, Yin XY, Yang Y, Duan JA, Li NG, Shi ZH.
Sun SL, et al. Among authors: zheng xr.
Biomed Pharmacother. 2023 Dec 31;169:115905. doi: 10.1016/j.biopha.2023.115905. Epub 2023 Nov 24.
Biomed Pharmacother. 2023.
PMID: 38000356
Free article.